

24 years of leveraging the business of Bio
www.biospectrumindia.co

SOLIQUA[®] soloStar[®]
 100 units/ml + 33 micrograms/ml
 solution for injection in a pre-filled pen

SOLIQUA[®] soloStar[®]
100 units/ml + 33 micrograms/ml
 solution for injection in a pre-filled pen
insulin glargine + lisinsenatide
Use only in this pen.
 Subcutaneous use
30-60 dose steps
 1 unit of insulin glargine + 8.33 micrograms of lisinsenatide
 dose of 3 penes x 3 x 3

SOLIQUA[®] soloStar[®]
 100 units/ml + 50 micrograms/ml
 solution for injection in a pre-filled pen
insulin glargine + lisinsenatide
Use only in this pen.
 Subcutaneous use
10-40 dose steps
 1 unit of insulin glargine + 8.33 micrograms of lisinsenatide
 dose of 3 penes x 3 x 3

SANOFI

Sanofi (India) has received marketing authorisation for its diabetes drug Soliqua (in pre-filled pen) from the Central Drugs Standard Control Organisation (CDSCO). Soliqua is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes who are insufficiently controlled on oral or injectable therapies. It comes in once daily dosing of pre-filled pens in fixed-ratio combination (10-40 and 30-60) of insulin glargine and lixisenatide.

Soliqua (10-40 and 30-60 prefilled pens) is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.

According to Dr Shalini Menon, Country Medical Lead, Sanofi (India), "Concerns about hypoglycemia and weight gain are known barriers when advancing diabetes treatments, more so when intensifying to a complex insulin regime. The global Solimix study that included Indian patients, demonstrated that once daily Soliqua provides with weight benefit and less hypoglycaemia when compared with twice daily premixed insulin – thereby becoming a valuable option for endocrinologists."